Yes, Zarxio (filgrastim-sndz) is used during chemotherapy to maintain white blood cell and absolute neutrophil counts by preventing chemotherapy-induced neutropenia.
Zarxio is FDA-approved specifically to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy 1. The drug works prophylactically rather than as a reactive treatment—it prevents dangerous drops in WBC and ANC rather than simply "maintaining" baseline counts.
How Zarxio Works in Chemotherapy
Zarxio stimulates neutrophil production after chemotherapy damages the bone marrow. The standard dosing is 5 mcg/kg/day administered subcutaneously, starting 1-3 days after chemotherapy completion 2, 1. This timing is critical—never give it within 24 hours before chemotherapy, as this can worsen outcomes 1.
Treatment Protocol
Start timing: Begin Zarxio 1-3 days after completing each chemotherapy cycle 2
Continue until: ANC reaches 2,000-3,000/mm³ or up to 2 weeks post-chemotherapy 2, 1
Stop if: ANC exceeds 10,000/mm³ to avoid excessive leukocytosis 1
Monitor: Check CBC twice weekly during therapy 1
A transient neutrophil increase occurs 1-2 days after starting Zarxio, but continue for the full duration to ensure sustained recovery 1.
Critical Evidence on Continuation
Continue Zarxio through ALL chemotherapy cycles, not just the first few. Women receiving prophylaxis only during the first 2 cycles had 36% febrile neutropenia rates versus 10% when receiving it through all 6 cycles 2. This represents a 3.6-fold increase in risk when stopping early.
Biosimilar Equivalence
Zarxio (filgrastim-sndz) is therapeutically equivalent to reference filgrastim (Neupogen). The ASCO guidelines explicitly state that pegfilgrastim, filgrastim, tbo-filgrastim, and filgrastim-sndz can all be used interchangeably for preventing febrile neutropenia 2. Real-world data confirms no differences in neutrophil recovery time, duration of therapy, or safety between Zarxio and reference filgrastim 3, 4.
Common Pitfalls to Avoid
- Don't wait for neutropenia to develop—Zarxio is prophylactic, not reactive
- Don't give it too close to chemotherapy—the 24-hour buffer before chemotherapy is mandatory 1
- Don't stop after 1-2 cycles—continue through the entire chemotherapy regimen 2
- Don't use arbitrary ANC thresholds—follow the 2,000-3,000/mm³ target for discontinuation 2
The choice between Zarxio and other G-CSFs depends on convenience, cost, and clinical situation 2. Zarxio offers significant cost savings compared to reference filgrastim with identical clinical outcomes 3.